BHB
ARCT icon

Bank Hapoalim BM’s Arcturus Therapeutics ARCT Stock Holding History

Bank Hapoalim BM’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,571
Closed -$11K – 202
2017
Q3 		$11K Hold
1,571
– – ﹤0.01% 216
2017
Q2 		$12K Hold
1,571
– – ﹤0.01% 210
2017
Q1 		$13K Buy
+1,571
New +$14.5K ﹤0.01% 207

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Bank Hapoalim BM's ARCT Position: Q4 2017 in Review

Bank Hapoalim BM sold out of Arcturus Therapeutics (ARCT) in Q4 2017, closing a stake of 1,571 shares — an estimated $11K sold.

Bank Hapoalim BM first reported a position in ARCT in Q1 2017 and held it in 3 quarters. The position peaked at $13K in Q1 2017. 19 funds tracked by Wall St. Rank hold ARCT as of Q4 2017.

  • Bank Hapoalim BM reported no remaining Arcturus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Bank Hapoalim BM sold 1,571 Arcturus Therapeutics shares in Q4 2017, an estimated $11K.
  • Bank Hapoalim BM first reported a position in Arcturus Therapeutics in Q1 2017 and held it in 3 quarters.
  • Bank Hapoalim BM's Arcturus Therapeutics position peaked at $13K in Q1 2017.
  • 19 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2017.

Based on Bank Hapoalim BM's 13F filing for Q4 2017, filed 5 Feb 2018.